the specific authorization required in S. 692, the amendment allows them to continue the operations of those games until a tribe's compact expires. The current language addressing technology that is included in most compacts does not contain the exact terminology as defined in S. 692.

Additionally, there are other states where language that addresses the current technology is not contained in the compact, but the state has consented to the use of technology. My amendment contains a "grandfather clause" for those operations, which will run until their compacts expire by their own terms. Once a tribe's compact expires, the compact must be renegotiated and will be required to contain language which conforms to the requirements of S. 692.

Contrary to the views of some, Indian tribes are not generally interested in operating games which are broadcast on the "world wide web" or the Internet, and in which a person sitting in their home may "log on" to a computer and begin placing bets.

Indian tribes are, however, interested in continuing the operations of the games they currently have, and which they have agreed with their states are legal. This amendment allows them to do just that.

Mr. FERINGOLD. Mr. President, I rise today to express my opposition to the Internet Gambling Prohibition Act of 1999. I voted against this bill when it was brought to the floor last year as an amendment to an appropriations bill. I did not object to the unanimous consent request to pass this bill in the closing days of this session, but I would like the record to reflect my continuing opposition to this bill.

Ms. COLLINS. Mr. President, I ask unanimous consent that the amendments be agreed to, the substitute amendment be agreed to, as amended, the bill be the third time and passed, as follows:

The amendment (No. 2783) was agreed to.

The amendment (No. 2782) was agreed to.

The committee amendment in the nature of a substitute, as amended, was agreed to.

The bill (S. 692), as amended, was read the third time and passed, as follows:

The bill was not available for printing. It will appear in a future edition of the RECORD.}

DATE-RAPE DRUG CONTROL ACT OF 1999

Ms. COLLINS. Mr. President, I ask unanimous consent that the Senate proceed to the consideration of Calendar No. 416, S. 461.

The PRESIDING OFFICER. Without objection, it is so ordered.

The bill (S. 692), as amended, was passed, the motion to reconsider be the bill be read the third time and amendments be agreed to, the substitute amendment be agreed to, as amended, the substitute, as amended, was agreed to.

The PRESIDING OFFICER. Without objection, it is so ordered.

The amendment (No. 2783) was agreed to.

The amendment (No. 2782) was agreed to.

The committee amendment in the nature of a substitute, as amended, was agreed to.

The bill (S. 692), as amended, was read the third time and passed, as follows:

The bill was not available for printing. It will appear in a future edition of the RECORD.}

DATE-RAPE DRUG CONTROL ACT OF 1999

Ms. COLLINS. Mr. President, I ask unanimous consent that the Senate proceed to the consideration of Calendar No. 416, S. 461.

The PRESIDING OFFICER. Without objection, it is so ordered.

The legislative clerk read as follows:

A bill to amend the Controlled Substance Act to add gamma hydroxybutyric acid and ketamine to the schedules of control substances, to provide for a national awareness campaign, and for other purposes.

There being no objection, the Senate proceeded to consider the bill which had been reported from the Committee on the Judiciary, with amendments as follows:

Matter proposed to be deleted is enclosed in brackets; new matter is printed in italic.]

SEC. 2. FINDINGS.

This Act may be cited as the "DATE-RAPE Drug Control Act of 1999".

This Act may be cited as the "Hillery J. Farias and Samantha Reid DATE-Rape Drug Control Prohibition Act of 1999". 

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled:

SECTION 1. SHORT TITLE.

This Act may be cited as the "DATE-RAPE Drug Control Act of 1999".

SECTION 1. SHORT TITLE.

This Act may be cited as the "DATE-RAPE Drug Control Act of 1999".

SEC. 2. ADDITION OF GAMMA HYDROXYBUTYRIC ACID AND KETAMINE TO SCHEDULES OF SUBSTANCES; GAMMA BUTYROLACTONE AS ADDITIONAL LIST I CHEMICAL.

(a) ADDITION TO SCHEDULES.—In general. Section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) is amended by adding at the end of section 1 the following:

"(d) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following substances having a depressant effect on the central nervous system, or which contains any of their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Gamma hydroxybutyric acid.

(2) Security of facilities.—For purposes of any requirements that relate to the physical security of registered manufacturers and registrants, including the distribution of gamma hydroxybutyric acid and its salts, isomers, and salts of isomers manufactured, distributed, or possessed in accordance with an exemption approved under section 505(i) of the Federal Food, Drug, and Cosmetic Act shall be treated as a controlled substance in schedule III under section 202(c) of the Controlled Substances Act.

(b) ADDITION TO SCHEDULE III.—Schedule III under section 202(c) of the Controlled Substances Act ...
Substances Act (21 U.S.C. 812(c)) is amended in—

(1) by redesignating (4) through (10) as (6) through (12), respectively; and
(2) by redesignating (3) as (4); and
(3) by inserting after (2) the following:

(‘‘5) In the case of gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained in a drug product for which an application has been approved under section 505 of the Federal Food, Drug, and Cosmetic Act; ‘‘

(4) by inserting after (4) (as so redesignated) the following:

‘‘5) In the case of gamma hydroxybutyric acid and its salts, isomers, and salts of isomers.’’.

(c) ADDITIONAL LIST I CHEMICAL.—Section 102(34) of the Controlled Substances Act (21 U.S.C. 802(34)) is amended—

(1) by redesigning subparagraph (X) as subparagraph (Y); and
(2) by inserting after subparagraph (W) the following subparagraph:

‘‘(X) Gamma butyrolactone.’’.

(d) RULE OF CONSTRUCTION REGARDING CONTROLLED SUBSTANCE ANALOGUES.—Section 201(h)(1) of the Controlled Substances Act (21 U.S.C. 801(h)(1)) is amended—

(1) in subparagraph (A), by striking ‘‘subparagraph (B)’’ and inserting ‘‘subparagraph (C)’’;
(2) by redesignating subparagraph (B) as subparagraph (C); and
(3) by inserting after subparagraph (A) the following new subparagraph (B):

‘‘(B) The designation of gamma butyrolactone or any other chemical as a listed chemical pursuant to paragraph (34) or (35) does not preclude a finding pursuant to subparagraph (A) that the chemical is a controlled substance analogue.’’.

(2) CONTROLLED SUBSTANCES IMPORT AND EXPORT REQUIREMENTS.—Section 401(b)(1)(C) of the Controlled Substances Act (21 U.S.C. 841(b)(1)(C)) is amended in the first sentence by inserting after ‘‘schedule I or II’’ the following:

‘‘gamma hydroxybutyric acid in schedule III.’’.

(2) CONFORMING AMENDMENT.—Section 401(b)(1)(D) of the Controlled Substances Act (21 U.S.C. 841(b)(1)(D)) is amended by inserting ‘‘(other than gamma hydroxybutyric acid) after schedule III.’’.

(3) REQUIREMENTS UNDER TITLE I.—Section 301(c) of the Controlled Substances Act (21 U.S.C. 827) is amended by adding at the end the following:

‘‘(2) by inserting after subparagraph (W) the following subparagraph:

‘‘(X) Gamma butyrolactone.’’.

SEC. 4. AUTHORITY FOR ADDITIONAL REPORTING REQUIREMENTS FOR GAMMA HYDROXYBUTYRIC ACID PRODUCTS IN SCHEDULE III.

Section 307 of the Controlled Substances Act (21 U.S.C. 827) is amended by adding at the end the following:

‘‘(h) In the case of a drug product containing gamma hydroxybutyric acid for which an application has been approved under section 505 of the Federal Food, Drug, and Cosmetic Act, the Attorney General may, in addition to any other requirements that apply under this section with respect to such a drug product, establish any of the following as reporting requirements:

(1) That every person who is registered as a manufacturer of bulk or dosage form, as a packager, repackager, labeler, rebale, or distributor shall report acquisition and disposition of the drug products, drug substance, bulk drug, and dosage forms on hand as of the close of business December 31, indicating whether materials are in storage or in process of manufacturing.

(2) That all annual inventory reports shall be filed no later than January 15 of the year following that for which the report is submitted and include additional data on both inventory increases, including purchases, transfers, and returns, and reductions from inventory, including sales, transfers, theft, destruction, and seizure, and shall provide data on material manufactured, manufactured from other material, used in manufacturing other material, and used in manufacturing dosage forms.

(3) That every person who is registered as a manufacturer of bulk or dosage form shall report any changes in manufacturing inventory and capacity, including inventory increases, decreases, and inventory balances.

(4) That all reports under this section must include the registrant’s registration number as well as the registration numbers of vendors, suppliers, and customers, sufficient to allow the Attorney General to track the receipt and distribution of drug products.

(5) That each dispensing practitioner shall maintain for each prescription the name of the prescribing practitioner, the prescribing practitioner’s Federal and State registration numbers, with the expiration dates of those registrations, verification that the prescribing practitioner possesses the appropriate registration to prescribe this controlled substance, the patient’s name and address, the name of the patient’s insurance provider and documentation by a medical practitioner licensed and registered to prescribe the drug of the patient’s medical need for the drug. Such information shall be available at the prescription and copying by the Attorney General.

(6) That Section 310(b)(3) (relating to mail order reporting) applies with respect to gamma hydroxybutyric acid in the same manner and in the same manner as such section applies with respect to the chemicals and drug products specified in subparagraph (a) of section 310(b)(3).”.

SEC. 5. DEVELOPMENT OF FORENSIC FIELD TESTS FOR GAMMA HYDROXYBUTYRIC ACID.

The Attorney General shall make a grant for the development of forensic field tests to assist law enforcement officials in detecting...
the presence of gamma hydroxybutyric acid and related substances.

SEC. 5. CONTROLLED SUBSTANCES ANALOGUES.
(a) RULE OF CONSTRUCTION CONCERNING CONTROLLED SUBSTANCE ANALOGUES.—Section 102(32) of the Controlled Substances Act (21 U.S.C. 802(32)) is amended—
(1) in subparagraph (A), by striking “subparagraph (B)” and inserting “subparagraph (C)”;
(2) by redesignating subparagraph (B) as subparagraph (C); and
(3) by inserting after subparagraph (A) the following new subparagraph (B):
“(B) The designation of gamma butyrolactone or any other chemical as a list chemical pursuant to paragraph (34) or (35) does not preclude a finding pursuant to subparagraph (A) of this paragraph that the chemical is a controlled substance analogue.”.

(b) DISTRIBUTION WITH INTENT TO COMMIT CRIME OF VIOLENCE.—Section 401(b)(7) of the Controlled Substances Act (21 U.S.C. 811(b)(7)) is amended by inserting “or controlled substance analogue” after “distributing

SEC. 6. DEVELOPMENT OF MODEL PROTOCOLS, TRAINING MATERIALS, FORENSIC FIELD TESTING, AND COORDINATION MECHANISM FOR INVESTIGATIONS AND PROSECUTIONS RELATING TO GAMMA HYDROXYBUTYRIC ACID, OTHER CONTROLLED SUBSTANCES, AND DESIGNER DRUGS.
(a) IN GENERAL.—The Attorney General, in consultation with the Administrator of the Drug Enforcement Administration and the Director of the Federal Bureau of Investigation, shall—
(1) develop—
(a) model protocols for the collection of toxicology specimens and the taking of victim statements in connection with investigations into and prosecutions related to possible violations of the Controlled Substances Act or other Federal or State laws that result in or contribute to rape, other crimes of violence, or other crimes involving abuse of gamma hydroxybutyric acid, other controlled substances, or so-called “designer drugs”; and
(b) model training materials for law enforcement personnel involved in such investigations; and
(2) make such protocols and training materials available to Federal, State, and local personnel responsible for such investigations.
(b) GRAND JURY.—(1) IN GENERAL.—The Attorney General shall make a grant, in such amount and to such public or private person or entity as the Attorney General considers appropriate, for the development of forensic field tests to assist law enforcement officials in detecting the presence of gamma hydroxybutyric acid and related substances.

(2) AUTHORIZATION OF APPROPRIATIONS.—There are authorized to be appropriated such sums as may be necessary to carry out this subsection.
(c) REPORT.—Not later than 180 days after the date of the enactment of this Act, the Attorney General shall submit to the Committees on the Judiciary of the Senate and House of Representatives a report which shall—
(1) set forth the recommendations of the special unit under subsection (b)(2); and
(2) specify the allocations and reallocations of resources that the Attorney General proposes to make in response to the recommendations.

SEC. 7. ANNUAL REPORT REGARDING DATE-RAPE DRUGS; NATIONAL AWARENESS CAMPAIGN.
(a) ANNUAL REPORT.—The Secretary of Health and Human Services (in this section referred to as the “Secretary”) shall, not later than the first day of each calendar year following the date of the enactment of this Act, submit to Congress reports each of which provides an estimate of the number of incidents of the abuse of date-rape drugs (as defined in section 102(32) of the Controlled Substances Act (21 U.S.C. 802(32)) that occurred during the most recent one-year period for which data are available. The first such report shall be submitted not later than January 15, 2000, and subsequent reports shall be submitted annually thereafter.

(b) NATIONAL AWARENESS CAMPAIGN.—
(1) DEVELOPMENT OF PLAN; RECOMMENDATIONS OF ADVISORY COMMITTEE.—
(A) IN GENERAL.—The Secretary, in consultation with the Attorney General, shall develop a plan for carrying out a national campaign to educate individuals described in subparagraph (A) on the following:
(i) The dangers of date-rape drugs.
(ii) The applicability of the Controlled Substances Act to such drugs, including penalties under such Act.
(iii) Recognizing the symptoms that indicate an individual may be a victim of such drugs, including symptoms with respect to sexual assault.
(iv) Appropriately responding when an individual has such symptoms.
(B) INTENDED POPULATION.—The individuals referred to in subparagraph (A) are young adults, youths, law enforcement personnel, educators, school nurses, counselors of rape victims, and emergency room personnel in hospitals.
(C) ADVISORY COMMITTEE.—Not later than 180 days after the date on which the national campaign under subparagraph (A) is established, the committee shall be composed of individuals who collectively possess expertise on the effects of date-rape drugs and on detecting and controlling the drugs.

(2) IMPLEMENTATION OF PLAN.—Not later than 180 days after the date on which the advisory committee under paragraph (1) is established, the consultation with the Attorney General, shall commence carrying out the national campaign under such paragraph in accordance with the plan developed under such subparagraph. The campaign may be carried out directly by the Secretary and through grants and contracts.

(3) EVALUATION BY GENERAL ACCOUNTING OFFICE.—Not later than two years after the date on which the national campaign under paragraph (1) is commenced, the Comptroller General of the United States shall submit to Congress an evaluation with respect to date-rape drugs of the national campaign.

(c) DEFINITION.—For purposes of this section, the term “date-rape drugs” means gamma hydroxybutyric acid and its salts, isomers, and salts of isomers and such other drugs or substances as the Secretary, after consultation with the Attorney General, determines to be appropriate.

SEC. 8. SPECIAL UNIT IN DRUG ENFORCEMENT ADMINISTRATION FOR ASSESSMENT OF ABUSE AND TRAFFICKING OF GHB AND OTHER CONTROLLED SUBSTANCES AND DRUGS.
(a) ESTABLISHMENT.—Not later than 60 days after the date of the enactment of this Act, the Attorney General shall establish within the Operations Division of the Drug Enforcement Administration a special unit which shall assess the abuse of and trafficking in gamma hydroxybutyric acid, flunitrazepam, ketamine, other controlled substances, and other so-called “designer drugs” whose use has been associated with sexual assault.

(b) PARTICULAR DUTIES.—In carrying out the assessment under subsection (a), the special unit shall—
(1) examine the threat posed by the substances and drugs referred to in that subsection on a national basis and regional basis; and
(2) make recommendations to the Attorney General regarding allocations and reallocations of resources in order to address the threat.

(c) REPORT ON RECOMMENDATIONS.—
(1) REQUIREMENT.—Not later than 180 days after the date of the enactment of this Act, the Attorney General shall submit to the Committees on the Judiciary of the Senate and House of Representatives a report which shall—
(A) set forth the recommendations of the special unit under subsection (b)(2); and
(B) specify the allocations and reallocations of resources that the Attorney General proposes to make in response to the recommendations.

SEC. 9. TECHNICAL AMENDMENT.
Section 401 of the Controlled Substances Act (21 U.S.C. 811) is amended by redesignating subsections (d), (e), (f), and (g) as subsections (c), (d), (e), and (f), respectively.

Amend the title so as to read: “An Act to amend the Controlled Substances Act to direct the emergency scheduling of gamma hydroxybutyric acid, to provide for a national awareness campaign, and for other purposes.”.

AMENDMENT NO. 2784
(Purpose: change in short title)
Ms. COLLINS, for the President, I send an amendment to the desk and ask for its immediate consideration.

The PRESIDING OFFICER. The clerk will report.

The legislative clerk read as follows:
The Senator from Maine [Ms. COLLINS], for Ms. Hutchison, proposes an amendment numbered 2784.
Ms. COLLINS. Mr. President, I am unanimous consent that reading of the amendment be dispensed with.

The PRESIDING OFFICER. Without objection, it is so ordered.

The amendment is as follows:
On page 1, beginning on line 4, strike “Samantha Reid and Hillory J. Farias” and insert “Hillery J. Farias and Samantha Reid”.

On page 6, line 21, strike “Samantha Reid and Hillory J. Farias” and insert “Hillery J. Farias and Samantha Reid”.

On page 7, line 12, strike “Samantha Reid and Hillory J. Farias” and insert “Hillery J. Farias and Samantha Reid”.

Ms. COLLINS. Mr. President, I ask unanimous consent that the amendment be agreed to, the amendment, as amended, be read to, and the bill be read the third time.
I further ask unanimous consent that the Senate proceed to the consideration of the House companion bill, H.R.
November 19, 1999

S. 1561, and its counterpart, H.R. 2130, are named for a young woman by the name of Samantha Reid. Samantha was born in the Henry Ford Hospital in Detroit on January 2, 1984. She grew up in Lincoln Park. She played trumpet in her elementary school band. She was a girl scout for eight years, with the help of her mother. Judi Clark, who was a drum leader. She also started 6th grade baseball player. She went on to attend Carlson High School in Gibraltar, where she played freshman basketball. Her favorite restaurant was McDonald’s, and her favorite meal there was a Big Mac. She loved to go to Cedar Point Amusement Park, and got mad if she couldn’t go at least twice a week. She earned her spending money by helping around the house with chores and babysitting, and indeed, on February 11, 1995, she earned an award for outstanding performance in their babysitting training from the City of Lincoln Park. Her mother called her “Hammy Sammy” because of the way she always smiled in pictures. Her older brother Charles Reid, who is 18, remembers and misses her loud voice.

On January 17, 1999, Samantha died a few weeks after turning 15. She and two friends, none of them yet 16, were at a party given by a 25-year-old man in Woodhaven, Michigan. Samantha Reid drank a Mountain Dew—a soft drink—and passed out within minutes. Her friend, Melanie Sindone, also 15, passed out as well. Melanie lapsed into a coma, but she has survived. Her friend, Melissa Sindone, also 15, passed out as well. Melanie lapsed into a coma, but she has survived. These two girls had no reason to believe that they were drinking anything dangerous. But they were wrong. Their drinks had been laced with the drug GHB, commonly known as a “date rape drug.” Samantha died instantly. GHB is especially dangerous because it is relatively easy to produce. Accord- ing to the DEA, the clandestine synthesis involves the use of two common, non-regulated chemicals: gamma-butyrolactone (GBL), the primary precursor chemical, and sodium hydroxide (lye). GBL is a solvent with a wide range of industrial uses. Tens of thousands of metric tons are produced annually and it is readily available from legitimate sources. The synthesis is a simple one-pot method requiring no special chemical expertise. In addition, kits for making GHB containing GBL and sodium hydroxide are being sold on the Internet. GBL, once absorbed from the gastrointestinal tract after oral administration, is read- ily converted to GHB in the body and produces the same profile of physiological and behavioral effects as GHB. The combination of the ease with which GHB can be produced and widespread ignorance about GHB’s dangers especially among our nation’s youth, has led the law enforcement community to view GHB as a serious and growing threat.

The Controlled Substances Act provides an administrative mechanism for the Attorney General, in consultation with the Secretary of HHS, to place dangerous substances susceptible of abuse on a “schedule” of controlled substances, thereby restricting access to them and imposing criminal penalties on their manufacture. The Attorney General and the Secretary are in agreement that GHB should in fact be scheduled, but they are in disagreement over which schedule it should be placed on. This is because GHB is currently under investiga- tional use as a means of treating narcolepsy and cataplexy, afflictions affecting about 70,000 Americans, and HHS has been understandably reluctant to agree that GHB belongs on Schedule I or II, which would carry the most serious penalties for illicit sale, because the security requirements that would accompany such scheduling would interfere with medical research. On the other hand, the DEA has been understandably reluctant to agree to any lesser scheduling, because the result would be lower penalties for the unauthorized sale and distribution of this drug. Moreover, under the Controlled Substances Act, the fact that GHB is under investigation for possible medical use precludes the Attorney General from using her emergency au- thority to schedule it as an “imminent hazard to the public safety.”

The result has been an administrativa- deadlock that has resulted in a complete failure to schedule GHB at all. Hence legislative intervention is needed.

This legislation has been drafted as a specific response to these various com- peting considerations, which the current scheduling categories are not all that well suited to handle in any event. Notwithstanding the current investigational medical use, the legislation determines that GHB is an imminent haz- ard to public safety. It therefore directs the Attorney General to place it on the schedule on which imminent hazards are ordinarily placed, which is Schedule I. It relaxes the physical security requirements that would ordi- narily apply to Schedule I substances for investigational use. The Federal inverted to the drug, however, following the rec-ommendation of the Secretary of HHS on what is appropriate in that area and thereby avoiding interfering with the
ongoing research. It also makes clear that should this research pay off with a drug that the FDA approves because it concludes that it would then responsibly be prescribed to treat narcolepsy, cataplexy, or other diseases, the FDA approved drug will be classified as a Schedule III drug, although the Attorney General to develop, and make available to Federal, State, and local law enforcement and communication devices, knowledge of the drug I've encountered in 25 years as a police officer. This is because of the overwhelming dangers of GHB. Consciousness of the dangers of this drug is lagging far behind the threat the drug presents, and it is critical that we make GHB a national priority to remedy that problem.

Finally, the legislation would direct the Attorney General to examine and recommend improvements to current mechanisms for coordinating federal, state, and local investigations and prosecutions in this area. And it would establish a special unit within the DEA to assess the federal response to the abuse and trafficking of GHB, other controlled substances, and other designer drugs associated with sexual assault, recommended any reallocations of enforcement resources necessary to improve that response, and direct the Attorney General to make any such reallocations she believes are appropriate.

It is time to act, Mr. President, to save young people, and young women in particular, from these deadly drugs and the predators who use them. I ask my colleagues to give their full support.

I also ask unanimous consent that a copy of the autopsy to review before including each death in the tally. Still, there was no reporting mechanism, no blanket means of educating the public, providing more standardized information to law enforcement, and developing testing procedures. It would be a giant step toward stopping the lies about GHB as a totally safe, wonder drug.

There being no objection, the letters were ordered to be printed in the RECORD.

Drugs—Teaching & Consulting,
Pasadena, CA, October 3, 1999.
Senator Spencer Abraham
Dirksen Senate Office Building,
Washington, DC.

DEAR SENATOR ABRAHAM: I am writing in support of Senator Bill 1561. For four years, my life has revolved around a world of drug abuse little known by law enforcement, medical personnel, or the public. I have watched MDMA explode worldwide in the rave, college and club scenes. I've seen flunitrazepam (Rohypnol, aka roofies) make its mark in the music and LSD will find its resurface. And, I've watched in horror as the drug gamma hydroxy butyrate (GHB) has marched coast to coast, plucking out young lives in its path, picking up momentum as it goes. I consider it simply the most dangerous drug I've encountered in 25 years as a police officer. This is because of the overwhelming amount of misinformation spread about GHB, the dramatic lack of real scientific knowledge of it, the difficulty in testing for it, and recognizing it in the street, and how easily and unpredictably it kills. GHB is indeed the Bad Child of the Internet. And, it has forever change the face of sexual assault investigations.

Despite a world brimming with technology and communication devices, knowledge of this drug has been based primarily on information via the Internet that runs the gamut from outland to totally false. Any drug abuser or drug pusher can get on the Internet and pump out volumes of lies and half truths unabated. There are thousands of websites designed to be the wonder drug that will cure anything you can think of and instructing everyone NOT to call 911 for the victim of a GHB overdose. Deadly advice in disregard of the over 30% of all drug overdose deaths involve GHB. The "system" has truly failed the American public on this drug. As a friend of Samantha Reid, the 15-year-old Maryland victim of GHB, appointed by President Clinton, "You tell us every day about marijuana and other drugs. Why didn't you tell us about GHB?" Daily, I am asked by the families who have lost loved ones to GHB—"I've never heard of this drug. Why, why didn't we know about this drug?"

Each day that GHB is not a federally controlled substance is another day of failure by the "system." No, controlling a drug does not solve the problem, but it allows additional resources to be plugged into the tasks of educating the public, providing more standardized information to law enforcement, and developing testing procedures. It would be a giant step toward stopping the lies about GHB as a totally safe, wonder drug.

There isn't a meaningful data collection mechanism to capture this. Existing systems are cumbersome, far behind in reporting statistics, and non-responsive to changing trends. In early 1997, the tally of GHB-related deaths known to the Enforcement Administration was seven. We knew that there was no way to put a figure on the possible number of deaths related to GHB. There were no laws under which the coroners knew to test for it. During our hearings before the California Legislature, Dennis Fraga showed up on the witness list. He arrived with autopsy report in hand, showing that his 25-year-old son, Jeffery, had died from alcohol and GHB ingestion. We realized that had we known about this death, there would have been more funding for the DEA to make inquires about the entire GHB problem in the country, and the death count rapidly jumped to 26. The death toll continued to slowly increase, based on word of mouth and reports by law enforcement. We began a campaign to get a copy of the autopsy to review before including each death in the tally. Still, there was no reporting mechanism, no blanket means of educating the public, providing more standardized information to law enforcement, and developing testing procedures. It would be a giant step toward stopping the lies about GHB as a totally safe, wonder drug.
element of burns from high pH levels. But that is not the entire story. When GHB is abused, aggressiveness and impulsive behavior are common. Substance abuse behaviors resulting in dangerous situations are usually the result of GHB abuse inappropriately combined with alcohol and other sedatives. This can lead to a very serious situation that can result in death. The fact remains that 25 year-olds don't die from a .17 blood alcohol; Jeffery Fraga died that night because he took GHB. Samantha Reid was drinking a Mountain Dew the night she died. And 20 year-olds don't die from sleeping face down on a pillow... unless in coma from GHB ingestion. I took it as a study (after reading on the Internet that it is "totally safe"), not a recreational drug. It is GHB that kills.

Not nearly enough is known about this drug from a medical and scientific viewpoint. The literature is old and outdated. New information is being learned daily and still not nearly enough is known. The old literature says GHB is not addictive. We know this to be untrue. In fact, withdrawal from GHB addiction is life threatening. This is simply not true anymore. Parents and law enforcement, prosecutors and distributors of GHB and analogs. What the GHB death toll speaks for itself. Legislation is needed to help our children, to allow for education targeting teens who have been introduced to drugs in an effort to protect and ultimately save them.

Mr. ABRAHAM. Mr. President, I would like to close by reading one letter that I received recently from Judy Clark, Samantha Reid's mother. "Better than anything I can say, makes the case as to why this legislation is needed now." She wrote this letter to the members of the Senate Judiciary Committee. It reads as follows;

To the Members of the Senate Judiciary Committee:
On January 17, 1999, I lost my only daughter, Samantha Reid, when GHB and/or GBL was slipped into her Mountain Dew soft drink. I knew nothing about GHB before this tragic event. I took six months off of work and began educating myself on GHB. The more I learned about this invisible predator, the more concerned for our nations safety I became.

I have joined Spencer Abraham on campaigning to pass S. 1561. This bill is long overdue in our country and contains many positive programs for awareness and will allow for education targeting teens who are now receiving false information on GHB. A new warning label will give many young ladies the information necessary to protect and ultimately save themselves from drug dependency. Other drugs have been developed in Schedule I. I personally do not think it will be GHB, but a safer, longer acting cousin that is yet to be developed.

I cannot imagine in my wildest dreams a company saying, "Oh excuse me, we are making too much money!!!!" If the Legislature is determined to deal with future issues, then I adamantly urge that this drug be specifically excluded from the "off label use" policy. Any use of GHB beyond narcolepsy/cataplexy would require its own proper research and development. As the drug company claims, their only interest is for narcolepsy/cataplexy patients, then simply no reason they would protest such a clause being included.

There is much work to be done on this drug in all arenas. The dangers of GHB need to be made crystal clear to America's youth and parents alike. Without a doubt, prosecutors and medical personnel are not uniformly prepared to handle cases involving GHB. GHB has brought to the sexual assault investigation a very real challenge to overcome. The law enforcement has an added horror for rape victims that I cannot even begin to address in this document. As a start, we need to standardize all medical personnel. This is a unbelievably challenge to overcome. Aggressive federal, state and local law enforcement are needed against manufacturers and distributors of GHB and analogs.

The GHB death toll speaks for itself. Legislation is needed to help our children, to allow for education targeting teens who have been introduced to drugs in an effort to protect and ultimately save themselves from drug dependency. Other drugs have been developed in Schedule I. I personally do not think it will be GHB, but a safer, longer acting cousin that is yet to be developed.

Not one more mother should have to go through what Judi Clark has. No one else should have to go through what this family has suffered. I am very determined to not only see this legislation pass, but also to work closely with the Department of Justice, the Drug Enforcement Agency, and State and local law enforcement agencies, to make sure this is just the first step in what will ultimately be a successful campaign to rid this Nation of the illicit use of this drug, and to make sure that children of our country are no longer the victims of predators who use it for criminal purposes. I yield the floor.

The PRESIDING OFFICER. The Chair recognizes the Senator from Michigan.

Ms. COLLINS. Mr. President, I commend the Senator from Michigan for his leadership and his eloquent statement.

Mr. HATCH. Mr. President, Today, the Senate adopted a significant measure against date rape and other heinous crimes associated with abusing certain types of drugs. I want to make a few comments on this bill, S. 1561, which addresses the abuse of the dangerous drug GHB, which has been used to commit date rape and other crimes.

As Chairman of the Senate Judiciary Committee, I am proud that it was a member of our Committee, Senator Spencer Abraham, who introduced and has played the key leadership role in the Senate passage of S. 1561. The Samantha Reid and Hillory J. Farias Date Rape Protection Act of 1999."

I am also proud that other members of the Judiciary Committee, Senators DeMINT, and FeINSTEIN have joined Senator Abraham in co-sponsoring this legislation.

It is only through the hard work and insistence of Senator Abraham that
this bill will pass the Senate today. I also want to commend his able staff, especially LEITCH and Chuck Butto, who has long been in the forefront of controlled substances and other drug abuse issues. I must also recognize the efforts of Marcia Lee of his staff for her diligence and creativity in developing this language.

I must also recognize the efforts of Chairmen Thomas B. Builey and Fred Upton for their work in developing and sheparding the House companion to S. 1561, H.R. 2310, through that body. In this regard, I must mention the efforts of John Manthei of the House Commerce Committee as well as Ms. Jane Williams of Rep. Upton's staff. Both of them deserve recognition for their dedication to passing this bill.

S. 1561 is concerned with the proper regulation of gamma hydroxy butyric acid, the chemical known on the street as GHB which has both hateful and hopeful uses. On one hand, many families across America have suffered due to abuse of this agent which has been used to lull unsuspecting women into a date-rape situation and has even resulted in death through overdose. On the other hand, GHB holds unprecedented promise to those one-quarter million Americans suffering from extreme sleep disorders such as cataplexy and narcolepsy.

Cataplexy is a debilitating condition suffered by some 70,000 Americans that results in an inability of the muscles to support the body. Narcolepsy, which attacks 170,000 Americans, causes a person suddenly and unpredictably to fall asleep. Neither of these terrible diseases have an effective treatment today. As author of the 1984 Orphan Drug Act which creates incentives for private sector drug firms to investigate treatments for rare diseases, I am particularly sensitive to the needs of families suffering from low-prevalence conditions. We need to do everything we can to get academic researchers and the pharmaceutical industry to find cures for the hundreds of currently untreatable rare diseases.

The problem for policymakers, both in the Congress and at the DEA, is how to encourage the use of the medically promising uses of GHB while discouraging and outlawing the illicit uses such as date rape.

While there are no known cases of diversion of this drug from the on-going and highly promising clinical trials of GHB as a treatment for cataplexy and narcolepsy, the problem of GHB abuse demands our attention.

According to DEA, hospital and law enforcement officials have reported about 5,500 cases of GHB abuse, including 49 deaths. Aggregate statistics, as alarming as they may be, cannot convey the absolute upheaval that GHB abuse can cause for an individual and a family.

Senator Abraham has told me the story about the untimely death of a bright and vivacious 15-year-old young woman from Michigan, Samantha Reid. She went to a small gathering of friends, was given a drink from a soft drink bottle laced with GHB, and died. Samantha did nothing wrong. Her mother, Judi Clark, did nothing wrong. Unfortunately, this tragedy has struck this family.

Four young men have been charged under Michigan law for involuntary manslaughter and poisoning. But, given the prevalence and, as the Reid case highlights, the potential severity of GHB abuse, it seems clear—and both public health and law enforcement officials agree on this—that this chemical warrants regulation under the Controlled Substances Act. That's exactly what S. 1561 and its House companion accomplish.

Some may raise a question about whether the federal Controlled Substances Act failed to operate in a fashion that could have prevented deaths or sexual assaults through abuse of GHB.

Although there have been reports of substantial GHB abuse for several years now, I do not know why the Attorney General and Secretary of Health and Human Services have been unable to resolve the matters that have precluded this drug from being scheduled through the normal procedures under the Controlled Substances Act. I don't know why it took until September of 1997 for the DEA to request FDA to analyze the mandatory factors relating to GHB. I don't know why it took until May 19, 1999 to get a response to this request. I don't know why DEA has not acted in the last six months to bring this matter to a conclusion through administrative means. It should not take an act of Congress to schedule a dangerous drug under the Controlled Substances Act.

I do know that part of the unjustifiable delay in the scheduling of GHB stemmed from the fact that there is a difference of opinion between DEA and FDA about how to schedule this drug. But that answer is not good enough. It is simply inadequate to tell a mother of a child like Samantha Reid, a promising young woman with her whole life ahead of her, that the system “just takes time” because two bureaucracies disagreed about how something so serious should be handled.

This situation points out that a significant breakdown in the system has occurred with respect to the scheduling of GHB. It behooves the Congress to deliberate more ways to make the key agencies, DEA and FDA, be more responsive in the future, rather than be forced to do their jobs for them. The lesson of GHB should not be to teach the agencies to wait for Congressional action whenever the bureaucracy cannot act.

Let me just say that as a general matter I do not favor legislative scheduling or rescheduling. By statute, the responsibility for scheduling is delegated to the experts at DOJ and HHS. The world is turned upside down when DOJ informs Congress, as if did on May 3, 1999, that: “DOJ believes that it is appropriate for the Congress to schedule GHB at this time.”

By any measure, a fair reading of the Controlled Substances Act places the primary responsibility for regulating dangerous drugs upon law enforcement and public health experts at the appropriate federal agencies. I do have a concern about Congress legislating on the safety and efficacy of individual drug products, especially before clinical testing or introduction into commerce commences. Nor should we allow the Congress to be placed in the position of making technical, scientific and law enforcement judgment whenever an individual drug product with an actual or potential legitimate medicinal use is determined by experts to warrant the application of the CSA.

I am firmly behind efforts to stop so-called “date rapes”; this is a despicable crime and the Federal Government should take action to make sure it does not occur. While I wholeheartedly applaud the efforts of the House to strike a blow against abuse of GHB, I am concerned about Congress getting directly involved in the scheduling process as the House mandated in adopting H.R. 2310. In this regard, I was my strong sense that rather than for Congress to legislatively schedule GHB, it would have more impact to amend the statute and direct DEA to implement the Surgeon General's recommendations that were issued back on May 19, 1999.

I will not take the time today to consider the full implications of a policy of legislative rescheduling. I do plan in the future to re-examine the scheduling provisions of the Controlled Substances Act.

At this point, let me elaborate further on some of the issues I have raised.

Subsections (b) and (c) of section 201 of the Controlled Substances Act identify eight criteria that must be taken into account in scheduling a drug. With respect to scheduling a drug, these factors are:

(1) Its actual or relative potential for abuse.
(2) Scientific evidence of its pharmacological effect, if known.
(3) The state of current scientific knowledge regarding the drug or other substance.
(4) Its history and current pattern of abuse.
(5) The scope, duration, and significance of abuse.
(6) What, if any, risk there is to the public health.

By any measure, a fair reading of the Controlled Substances Act places the primary responsibility for regulating dangerous drugs upon law enforcement and public health experts at the appropriate federal agencies. I do have a concern about Congress legislating on the safety and efficacy of individual drug products, especially before clinical testing or introduction into commerce commences. Nor should we allow the Congress to be placed in the position of making technical, scientific and law enforcement judgment whenever an individual drug product with an actual or potential legitimate medicinal use is determined by experts to warrant the application of the CSA.

I am firmly behind efforts to stop so-called “date rapes”; this is a despicable crime and the Federal Government should take action to make sure it does not occur. While I wholeheartedly applaud the efforts of the House to strike a blow against abuse of GHB, I am concerned about Congress getting directly involved in the scheduling process as the House mandated in adopting H.R. 2310. In this regard, I was my strong sense that rather than for Congress to legislatively schedule GHB, it would have more impact to amend the statute and direct DEA to implement the Surgeon General's recommendations that were issued back on May 19, 1999.

I will not take the time today to consider the full implications of a policy of legislative rescheduling. I do plan in the future to re-examine the scheduling provisions of the Controlled Substances Act.

At this point, let me elaborate further on some of the issues I have raised.

Subsections (b) and (c) of section 201 of the Controlled Substances Act identify eight criteria that must be taken into account in scheduling a drug. With respect to scheduling a drug, these factors are:

(1) Its actual or relative potential for abuse.
(2) Scientific evidence of its pharmacological effect, if known.
(3) The state of current scientific knowledge regarding the drug or other substance.
(4) Its history and current pattern of abuse.
(5) The scope, duration, and significance of abuse.
(6) What, if any, risk there is to the public health.

By any measure, a fair reading of the Controlled Substances Act places the primary responsibility for regulating dangerous drugs upon law enforcement and public health experts at the appropriate federal agencies. I do have a concern about Congress legislating on the safety and efficacy of individual drug products, especially before clinical testing or introduction into commerce commences. Nor should we allow the Congress to be placed in the position of making technical, scientific and law enforcement judgment whenever an individual drug product with an actual or potential legitimate medicinal use is determined by experts to warrant the application of the CSA.

I am firmly behind efforts to stop so-called “date rapes”; this is a despicable crime and the Federal Government should take action to make sure it does not occur. While I wholeheartedly applaud the efforts of the House to strike a blow against abuse of GHB, I am concerned about Congress getting directly involved in the scheduling process as the House mandated in adopting H.R. 2310. In this regard, I was my strong sense that rather than for Congress to legislatively schedule GHB, it would have more impact to amend the statute and direct DEA to implement the Surgeon General's recommendations that were issued back on May 19, 1999.

I will not take the time today to consider the full implications of a policy of legislative rescheduling. I do plan in the future to re-examine the scheduling provisions of the Controlled Substances Act.

At this point, let me elaborate further on some of the issues I have raised.

Subsections (b) and (c) of section 201 of the Controlled Substances Act identify eight criteria that must be taken into account in scheduling a drug. With respect to scheduling a drug, these factors are:

(1) Its actual or relative potential for abuse.
(2) Scientific evidence of its pharmacological effect, if known.
(3) The state of current scientific knowledge regarding the drug or other substance.
(4) Its history and current pattern of abuse.
(5) The scope, duration, and significance of abuse.
(6) What, if any, risk there is to the public health.
November 19, 1999

CONGRESSIONAL RECORD—SENATE

(7) Its psychic or physiological dependence liability.

(8) Whether the substance is an immediate precursor of a substance already controlled under this title.

The statute proscribes that:

The recommendations of the Secretary of Health and Human Services to the Attorney General shall be binding on the Attorney General as to such scientific and medical matters, and if the Secretary recommends that a drug or other substance not be controlled, the Attorney General shall not control the drug or other substances.

This is the section of the law which appears not to have functioned optimally in the case of GHB. We can, and should, do better in anticipating and combating the next GHB.

To a large degree, the legislation we adopt today implements the May 19, 1999 HHS recommendations and the accompanying "Triage Factor Analysis Report" that take into account both the illicit abuse of GHB as well as the highly promising legitimate uses of this substance. While I believe that the language worked out by Senators Abraham and McCollum, and the DEA, is preferable to the earlier versions of the bill, I remain troubled by some aspects of how the current statute has worked and may work in the future.

First, I am troubled that if we place promising pharmaceutical candidates such as GHB into Schedule I of the Controlled Substance Act we undermine its integrity of the CSA and will discourage the legitimate, potential life-saving uses of such compounds. According to the statute, one of the three requirements of schedule I is that there is "no accepted medical use" in the United States. But the May 19, 1999 HHS recommendation has already found that the decataxeply product has cleared this hurdle.

The abuse potential of GHB, when used under an authorized research protocol, is consistent with substances typically controlled under Schedule IV. An authorized formulation of GHB is far enough along in the development process to meet the standard under Schedule II of a drug or substance having a "currently accepted medical use with severe restrictions." Under these circumstances, HHS recommends placing authorized formulations of GHB in Schedule III.

I hasten to point out that I have advocated stiffening the penalties for abuse of date-rape drugs such as GHB.

In 1997 I successfully led the charge to enact a law that imposed schedule I-level penalties for another date rape drug, flunitrazepam. This product was marketed for medical purposes overseas and did not meet the Schedule I requirement that "there is lack of accepted safety for use of the drug or other substance under medical supervision." Therefore, the Congress passed my legislation to increase the penalties for this drug. But we stopped short of scheduling the pharmaceutical into Schedule I, recognizing that the product does have accepted medical uses. It was my hope that this could be the model for GHB legislation as well.

I want to work constructively with my colleagues in Congress to achieve our common goals of taking immediate action against GHB, preserving the integrity of the CSA, and sending a strong message to those agencies charged with implementing the CSA that they must work together in a cooperative and expedient way to protect the American public.

While I think the bill we adopt today might have been written differently, I agree with my colleagues that our foremost goal must be to take quick and decisive action with respect to the criminalization of GHB used for non-medical purposes. Senator Abraham's bill is a good bill and he deserves a lot of credit for putting this improved legislative package together.

Let me also note that the bill we have just passed includes language I drafted requiring DEA to create a Special Unit to assess the abuse and trafficking of GHB and other date rape drugs, and will identify the threats posed by date rape drugs on a national and regional basis. I am pleased to be the sponsor of S. 47, the bill that creates this Special Unit. S. 47 has been incorporated in the final language that we adopt today. I can assure all my colleagues that this is one Senator that will closely review the Attorney General's report on the allocation and reallocation of resources to combat date rape and other crimes related to designer drugs.

We can and should look further into the problems associated with the scheduling of drugs under CSA and whether we need to change the relevant laws. But today we honor the recommendations of the CSA, and I look forward to continuing this discussion with Senator Abraham and Samantha Reid by taking an act that will hopefully reduce the risk of GHB abuse being visited upon unsuspecting women.

ELECTRONIC BENEFIT TRANSFER INTEROPERABILITY AND PORTABILITY ACT OF 1999

Ms. COLLINS. Mr. President, I ask unanimous consent that the Agriculture Committee be discharged from further consideration of S. 1733, and that the Senate then proceed to its immediate consideration.

The PRESIDING OFFICER. Without objection, it is so ordered.

The clerk will report the bill by title. The legislative clerk read as follows:

A bill (S. 1733) to amend the Food Stamp Act of 1977 to provide for a national standard of interoperability and portability applicable to electronic food stamp benefit transactions.

There being no objection, the Senate proceeded to consider the bill.

Ms. COLLINS. Mr. President, there is a substitute amendment at the desk submitted by Senator Fitzgerald, and I ask for its consideration.

The PRESIDING OFFICER. The clerk will report.

The legislative clerk read as follows:

The Senator from Maine (Ms. Collins), for Mr. Fitzgerald, proposes an amendment numbered 2785.

Strike all after the enacting clause and insert the following:

SECTION 1. SHORT TITLE.

This Act may be cited as the "Electronic Benefit Transfer Interoperability and Portability Act of 1999".

SECTION 2. PURPOSES.

The purposes of this Act are—

(1) to protect the integrity of the food stamp program;

(2) to ensure cost-effective portability of food stamp benefits across State borders without imposing additional administrative expenses for special equipment to address problems relating to the portability;

(3) to enhance the flow of interstate commerce involving electronic transactions involving food stamp benefits under a uniform national standard of interoperability and portability;

(4) to eliminate the inefficiencies resulting from a patchwork of State-administered systems and regulations established to carry out the food stamp program.

SECTION 3. INTEROPERABILITY AND PORTABILITY OF FOOD STAMP TRANSACTIONS.

Section 7 of the Food Stamp Act of 1977 (7 U.S.C. 1996) is amended by adding at the end the following:

"(k) INTEROPERABILITY AND PORTABILITY OF ELECTRONIC BENEFIT TRANSFER TRANSACTIONS.—

"(1) DEFINITIONS.—In this subsection:

"(A) ELECTRONIC BENEFIT TRANSFER CARD.—The term 'electronic benefit transfer card' means a card that provides benefits under this Act through an electronic benefit transfer service (as defined in subsection (1)(B)) supported by an electronic benefit transfer contract.

"(B) ELECTRONIC BENEFIT TRANSFER CONTRACT.—The term 'electronic benefit transfer contract' means a contract that provides for the issuance, use, or redemption of coupons in the form of electronic benefit transfer cards.

"(C) INTEROPERABILITY.—The term 'interoperability' means a system that enables a coupon issued in the form of an electronic benefit transfer card to be redeemed in any State.